30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Reimbursement / Regulatory

FDA Accepts Vericel's BLA for MACI for in Knee Cartilage Defects -

FDA has accepted for filing Vericel's Biologics License Application for MACI™ (matrix applied characterized autologous cultured chondrocytes), an investigational autologous cellular product intended to treat adult symptomatic knee cartilage defects.  FDA provided a PDUFA (Prescription Drug User Fee Act) goal date of 1/3/17, and does not plan to convene an advisory committee meeting to discuss the application.

Vericel submitted the BLA in early January 2016

Source: Vericel Corporation

This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.